Zobrazeno 1 - 10
of 195
pro vyhledávání: '"A M, Wardley"'
Autor:
Nicholas C. Turner, A. Douglas Laird, Melinda L. Telli, Hope S. Rugo, Audrey Mailliez, Johannes Ettl, Eva-Maria Grischke, Lida A. Mina, Judith Balmaña, Peter A. Fasching, Sara A. Hurvitz, Julia F. Hopkins, Lee A. Albacker, Jijumon Chelliserry, Ying Chen, Umberto Conte, Andrew M. Wardley, Mark E. Robson
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-9 (2023)
Abstract These analyses explore the impact of homologous recombination repair gene mutations, including BRCA1/2 mutations and homologous recombination deficiency (HRD), on the efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib i
Externí odkaz:
https://doaj.org/article/38e11546389a453baf13464d8594cd8f
Autor:
Belinda Kingston, Rosalind J. Cutts, Hannah Bye, Matthew Beaney, Giselle Walsh-Crestani, Sarah Hrebien, Claire Swift, Lucy S. Kilburn, Sarah Kernaghan, Laura Moretti, Katie Wilkinson, Andrew M. Wardley, Iain R. Macpherson, Richard D. Baird, Rebecca Roylance, Jorge S. Reis-Filho, Michael Hubank, Iris Faull, Kimberly C. Banks, Richard B. Lanman, Isaac Garcia-Murillas, Judith M. Bliss, Alistair Ring, Nicholas C. Turner
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Circulating tumour DNA can provide useful information on disease burden. Here, the authors analysed circulating tumour DNA from 800 patients from a breast cancer clinical trial and investigate the subclonal nature of the disease, and identify DNA mut
Externí odkaz:
https://doaj.org/article/5f176e5d5bcb4792adb4ec1effb35966
Autor:
Mark Verrill, Andrew M. Wardley, Jenny Retzler, Adam B. Smith, Catherine Bottomley, Sorcha Ní Dhochartaigh, Irwin Tran, Iain Leslie, Peter Schmid
Publikováno v:
Health and Quality of Life Outcomes, Vol 18, Iss 1, Pp 1-12 (2020)
Abstract Background The impact of different disease stages and treatment for human epidermal growth factor 2 positive (HER2-positive) breast cancer (BC) on work productivity and health-related quality of life (HRQoL) is poorly understood. Methods Thi
Externí odkaz:
https://doaj.org/article/7186bf7cdf9941deb767ba39a730ed29
Autor:
Helena Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi, Karen McAdam, Luke Hughes-Davies, Daniel Rea, Donna Howe, Kerry Raynes, Helen B Higgins, Maggie Wilcox, Chris Plummer, Betania Mahler-Araujo, Elena Provenzano, Anita Chhabra, Sophie Gasson, Claire Balmer, Jean E Abraham, Carlos Caldas, Peter Hall, Bethany Shinkins, Christopher McCabe, Claire Hulme, David Miles, Andrew M Wardley, David A Cameron, Janet A Dunn
Publikováno v:
Health Technology Assessment, Vol 24, Iss 40 (2020)
Background: The addition of adjuvant trastuzumab to chemotherapy has significantly improved outcomes for people with human epidermal growth factor receptor 2 (HER2)-positive, early, potentially curable breast cancer. Twelve months’ trastuzumab, tes
Externí odkaz:
https://doaj.org/article/66820d8dae1b478ea55fa5063313fffe
Autor:
Louise Hiller, Janet A. Dunn, Shrushma Loi, Anne-Laure Vallier, Donna L. Howe, David A. Cameron, David Miles, Andrew M. Wardley, Helena M. Earl
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background Twelve months treatment is the current standard of care for adjuvant trastuzumab in patients with HER2 positive early breast cancer however the optimal duration is not known. Persephone is a non-inferiority randomised controlled t
Externí odkaz:
https://doaj.org/article/3428b56c983c4bb691972bfa1e9a8297
Autor:
Belinda Kingston, Rosalind J. Cutts, Hannah Bye, Matthew Beaney, Giselle Walsh-Crestani, Sarah Hrebien, Claire Swift, Lucy S. Kilburn, Sarah Kernaghan, Laura Moretti, Katie Wilkinson, Andrew M. Wardley, Iain R. Macpherson, Richard D. Baird, Rebecca Roylance, Jorge S. Reis-Filho, Michael Hubank, Iris Faull, Kimberly C. Banks, Richard B. Lanman, Isaac Garcia-Murillas, Judith M. Bliss, Alistair Ring, Nicholas C. Turner
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-1 (2021)
Externí odkaz:
https://doaj.org/article/c4a8fb81f49749e99d11db28fb611c64
Autor:
Mark E. Robson, Alison L. Hannah, Colombe Chappey, Andrew M. Wardley, Sara A. Hurvitz, Peter A. Fasching, Judith Balmaña, Lida A. Mina, Eva-Maria Grischke, Johannes Ettl, Audrey Mailliez, Hope S. Rugo, Melinda L. Telli, Nicholas C. Turner
Purpose:To assess talazoparib activity in germline BRCA1/2 mutation carriers with advanced breast cancer.Patients and Methods:ABRAZO (NCT02034916) was a two-cohort, two-stage, phase II study of talazoparib (1 mg/day) in germline BRCA mutation carrier
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0521b112f8ed3c590acb4ef4037377f9
https://doi.org/10.1158/1078-0432.c.6528725.v1
https://doi.org/10.1158/1078-0432.c.6528725.v1
Autor:
Mark E. Robson, Alison L. Hannah, Colombe Chappey, Andrew M. Wardley, Sara A. Hurvitz, Peter A. Fasching, Judith Balmaña, Lida A. Mina, Eva-Maria Grischke, Johannes Ettl, Audrey Mailliez, Hope S. Rugo, Melinda L. Telli, Nicholas C. Turner
This supplementary appendix contains a listing of all the investigators involved in the ABRAZO study. It also includes information regarding key eligibility criteria for the study. Finally, a figure showing progression-free survival and overall survi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ba9d0e1909a4f7a52bd9fb8173599b9
https://doi.org/10.1158/1078-0432.22474217
https://doi.org/10.1158/1078-0432.22474217
Autor:
Maria Coakley, Prithika Sritharan, Guillermo Villacampa, Claire Swift, Kathryn Dunne, Lucy Kilburn, Katie Goddard, Patricia Rojas, Andy Joad, Warren Emmett, Charlene Knape, Karen Howarth, Peter S. Hall, Catherine Harper-Wynne, Tamas Hickish, Iain Macpherson, Alicia F. Okines, Andrew M. Wardley, Duncan Wheatley, Simon Waters, Rosalind Cutts, Isaac Garcia-Murillas, Judith Bliss, Nicholas Turner
Publikováno v:
Cancer Research. 83:PD5-03
Background: Detection of circulating tumour DNA (ctDNA) in patients (pts) who have completed treatment for early-stage breast cancer is associated with a high risk of future relapse. Identifying those at high risk of subsequent relapse may allow tail
Autor:
Matthew C Winter, Daniel Rea, Jacinta Abraham, Olga Oikonomidou, Iain R. Macpherson, David Cameron, Jeremy P Braybrooke, Sarah Kernaghan, Andrew M Wardley, Heidrun Gevensleben, Laura Moretti, Mark Tuthill, Katrina Randle, Peter Stephens, A Ring, Mike Hubank, Judith M Bliss, Rebecca Roylance, Abeer M Shaaban, Hannah Bye, Lucy Kilburn, Sue Martin, B Kingston, Katie Wilkinson, Nicholas C. Turner, Claire Snowdon, Ros Cutts, Richard D. Baird
Publikováno v:
C Turner, N, Kingston, B, S Kilburn, L, Kernaghan, S, M Wardley, A, R Macpherson, I, D Baird, R, Roylance, R, Stephens, P, Oikonomidou, O, P Braybrooke, J, Tuthill, M, Abraham, J, C Winter, M, Bye, H, Hubank, M, Gevensleben, H, Cutts, R, Snowdon, C, Rea, D, Cameron, D A, Shaaban, A, Randle, K, Martin, S, Wilkinson, K, Moretti, L, Bliss, J M & Ring, A 2020, ' Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial ', The Lancet Oncology, vol. 21, no. 10, pp. 1296-1308 . https://doi.org/10.1016/S1470-2045(20)30444-7
BACKGROUND: Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the accuracy of ctDNA testing in advanced breast cancer and